The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay

Journal of Gastroenterology

Volumn 51, Issue 1, 2016, Pages 63-70

  Kan, Toshiki ^a   Hashimoto, Senju ^a   Kawabe, Naoto ^a   Murao, Michihito ^a   Nakano, Takuji ^a   Shimazaki, Hiroaki ^a   Nakaoka, Kazunori ^a   Ohki, Masashi ^a   Takagawa, Yuka ^a   Kurashita, Takamitsu ^a   Takamura, Tomoki ^a   Yoshioka, Kentaro ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Direct acting antiviral agents; Hepatitis C virus; IL28B; PCR invader assay; Resistance associated variants

Indexed keywords

INTERFERON; INTERLEUKIN 28B; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN; VIRUS RNA;

AGED; ARTICLE; CLINICAL FEATURE; DRUG SENSITIVITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ANTIVIRAL RESISTANCE; BLOOD; GENETIC VARIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; PROCEDURES; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84953359871     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1080-1     Document Type: Article

References (28)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.
2. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47–56.
3. Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection. Liver Int. 2015;35(Suppl 1):56–64.
4. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res. 2009;39:1056–63.
5. Manns MP, Markova AA, Calle Serrano B, et al. Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int. 2012;32(Suppl 1):27–31.
6. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49:138–47.
7. Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238–248.
8. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91.
9. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.
10. Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? J Hepatol. 2014;61:1430–3.
11. He Y, Staschke KA, Tan SL. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In: Tan SL, editor. Hepatitis C viruses: genomes and molecular biology. Wymondham: Horizon Bioscience; 2006. p. 267–92.
12. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81.
13. El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008;48:38–47.
14. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201–7.
15. Tadokoro K, Suzuki F, Kobayashi M, et al. Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay. Kanzo. 2014;55:720–2.
16. Nishikawa T, Hashimoto S, Kawabe N, et al. Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. World J Gastroenterol. 2014;20:1289–97.
17. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.
18. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.
19. Itakura J, Kurosaki M, Takada H, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy. Hepatol Res. 2015. doi:10.1111/hepr.12474.
20. Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.
21. Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360–7.
22. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.
23. Shimada N, Toyoda H, Tsubota A, et al. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol. 2014;49:1485–94.
24. Chayama K, Hayes CN, Yoshioka K, et al. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol. 2011;46:545–55.
25. Taguchi T, Nagano-Fujii M, Akutsu M, et al. Hepatitis C virus NS5A protein interacts with 2′,5′-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol. 2004;85:959–69.
26. Choi YW, Tan YJ, Lim SG, et al. Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun. 2004;318:514–9.
27. Shi ST, Polyak SJ, Tu H, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology. 2002;292:198–210.
28. Cheng D, Zhang L, Yang G, et al. Hepatitis C virus NS5A drives a PTEN-PI3 K/Akt feedback loop to support cell survival. Liver Int. 2014. doi:10.1111/liv.12733.